2002 Cell Biology Pharmacokinetics 
Drug Target Review
NOVEMBER 1, 2023
2,8-10 However, the number of compounds with satisfying pharmacokinetic parameters (PKD) are limited, with most unable to cross the blood-brain barrier or go sufficiently deep into a malignant tumour. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. Nat Commun.
New Drug Approvals
JANUARY 9, 2024
As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,
Expert insights. Personalized for you.
134 
Let's personalize your content